Journal of Science: Tumor-targeted CD28 dual-specific antibodies enhance the anti-tumor effect of PD-1 immunotherapy.

!--Webeditor: page title" -- /---/ -- Although immunotherapy has gained a growing pro allred role in innovative cancer treatments, it is still not perfect--- many tumors do not respond at all.
we were saved by a growing class of engineering proteins, whose names are very specific, called dual-specific antibodies.
as the name suggests, these proteins have dual recognition capabilities: they are modified to target T-cell surface subjects and can also bind to the surface antigens of cancer cells.
their purpose is to bind the two types of cells together and activate the T-cell's ability to destroy tumors.
U.S. biotech company Regeneron Pharmaceuticals is working on a dual-specific antibody.
the company has attracted attention for its development of REGN-EB3.
REGN-EB3 is a mixture of three antibodies that outperformed other research candidates in treating Ebola virus infection last year.
the drug is under review by the U.S. Food and Drug Administration and is expected to be fully approved later this year.
regeneron are also working on antibody-based drugs to prevent or treat COVID-19 according to patients' needs.
, Regeneron's anti-cancer innovation platform has developed in a grim reality: certain cancers have developed deceptive strategies that allow them to resist immunotherapy.
cancer is as annoying as the infection caused by drug-resistant bacteria.
several common cancers have a noteworthy history of suppressing immunosuppressive checkpoint blocking therapy.
-checkpoint blocking therapy is a treatment that relies on the power of T-cells to kill tumors.
these research-specific antibodies are designed to help overcome cancer cell resistance.
Janelle Waite and Dimitris Skokos, members of a larger Regeneron research team, are testing whether a class of co-irritating CD28 dual-specific antibodies enhances anti-tumor activity.
study was recently published in the journal Science Translational Medicine under the title "Tumor-targeted CD28 bispecific antibodies anti-enhance the antitumor efficacy of PD-1 immunotherapy".
photo from Pixabay/CC0 Public Domain.
immune checkpoint blocking therapy itself is an innovative form of cancer treatment that relies on drugs called immunosuppressants.
therapy is designed to treat many forms of cancer by involving the body's immune system---, its T-cells, in identifying and attacking malignant tumor cells.
Keytruda, a drug that helps revolutionized the treatment of non-small cell lung cancer, is an immuno-checkpoint inhibitor.
immune checkpoint inhibitors are based on a seemingly simple principle: cancer cells have a protein called PD-L1.
T cells have a surface protein called PD1.
cunning cancer cells use their PD-L1 proteins to evade T-cells and pass immune checkpoints, allowing tumors to proliferate and spread.
a variety of cancers, from Hodgkin's lymphoma to lung, bladder, ovarian and kidney cancers, may initially respond to immunosuppressants, but can quickly become resistant.
regeneron team studied two double-specific antibodies that target a T-cell protein called CD28.
same time, they analyzed two tumor-specific antigens.
these two dual-specific antibodies bind to both T-cells and cancer antigens, enhancing the potential of T-cells to kill cancer cells.
Waite and colleagues found that these dual-specific antibodies enhanced the therapeutic effect of anti-PD-1 immuno checkpoint blocking in mouse models.
they also say the combination makes previously resistant tumors sensitive.
these two-specific antibodies showed little signs of toxicity and did not trigger a dangerous systemic reaction in T-cells.
Waite writes, "Monoclonal antibodies that block procedural cell death checkpoints (PD-1) have revolutionized cancer immunotherapy, however, many major tumor types remain unresponsive against PD-1 therapy, and even in responding tumor types, most patients do not develop long-lasting anti-tumor immunity."
" in a series of animal studies, Waite and his colleagues confirmed that their experimental bipedal and force antibodies, or bisexual antibodies, can safely improve immune checkpoint blocking immunotherapy's ability to kill cancer in mice.
these animals tend to be resistant to immunotherapy.
results represent a major step forward in building a safer combination of cancer immunotherapy, they report.
addition to mice, long-tailed macaques are also well resistant to these two-specific antibodies, and there are no serious immune side effects from similar treatments in the past.
study was carried out in a worldwide effort to address the resistance of tumor cells to immunosuppression.
year, French scientists raised the issue of rotavirus vaccines that can be used to overcome cancer cell resistance to immune checkpoint blocking immunotherapy.
Tala Shekarian, of the Lyon Cancer Research Centre in France, said: "We found that rotavir vaccines Rotateq and Rotanix have both immunostatulation and tumor-soluble properties.
," she added, the vaccines "can directly kill cancer cells with immunogenic cell death characteristics."
like Waite and his colleagues, Shekarian found a way to overcome the resistance of tumor cells.
French scientists also stressed the importance of using a cheap, off-the-go solution to the thorny problems of cancer treatment.
(bioon.com) Reference: 1.Janelle C. Waite et al. Tumor-targeted CD28 bispecificbodies anti-enhance the antitumor efficacy of PD-1 immunotherapy. Science Translational Medicine, 2020, doi:10.1126/scitranslmed.aba2325.!--/ewebeditor:page--!--ewebeditor:page title="--2.Scientists test a 'bispecific' antibody helps on-the-on-the-cancer.